The clinical utility and validity of preimplantation genetic testing for aneuploidies (PGT-A) in IVF practice is often questioned. Some major societies (Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology 2024) have released ambiguous statements about PGT-A, leaving the potential and benefits of embryo selection, enhanced by chromosome profile assessments, indeterminant. The Preimplantation Genetic Diagnosis International Society (PGDIS) Task Group has gathered the scientific information and critically evaluated the evidence about the clinical value of PGT-A. We considered technical aspects, genetic principles and clinical outcome studies, and conclude that the proper implementation of PGT-A results in increased benefits for IVF embryo selection. It is envisioned that this report will remove some of the confusion surrounding PGT-A, lead to informed choices about the use of PGT-A and ultimately result in improved transfer outcomes.